New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:24 EDTINSMInsmed data likely supports accelerated approval in NTM, says Piper Jaffray
Piper Jaffray believes Insmed's data for Arikayce in nontuberculous mycobacteria is likely to support accelerated approval, especially if the relapse rate is modest. Piper says recent data for Arikayce has caused "considerable controversy" and it reiterates an Overweight rating on shares of Insmed.
News For INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
18:51 EDTINSMOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTINSMInsmed files to sell 10M shares of common stock
Subscribe for More Information
March 24, 2015
13:54 EDTINSMInsmed personnel strong, says Piper Jaffray
After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.
March 23, 2015
09:06 EDTINSMInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
March 20, 2015
09:25 EDTINSMInsmed to host analyst and investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use